Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Agenus Inc.
DescriptionAnti-OX40 agonist antibody
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 4 (OX40) (TNFRSF4) (CD134)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat advanced or metastatic solid tumors; Treat solid tumors
Regulatory Designation
PartnerIncyte Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today